Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.

Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A.

Radiother Oncol. 2019 Jun 29;140:105-109. doi: 10.1016/j.radonc.2019.06.018. [Epub ahead of print]

PMID:
31265940
2.

Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.

Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):621-629. doi: 10.1016/j.clon.2019.05.001. Epub 2019 May 21.

PMID:
31126725
3.

5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed.

Martell K, Cheung P, Morton G, Chung H, Deabreu A, Zhang L, Pang G, Alayed Y, Mamedov A, Gladwish A, Loblaw A.

Pract Radiat Oncol. 2019 May 16. pii: S1879-8500(19)30122-5. doi: 10.1016/j.prro.2019.04.010. [Epub ahead of print]

PMID:
31103715
4.

Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.

Alayed Y, Loblaw A, Chu W, Al-Hanaqta M, Chiang A, Jain S, Chung H, Vesprini D, Morton G, Ravi A, Davidson M, Deabreu A, Mamedov A, Zhang L, Erler D, Cheung P.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1066-1073. doi: 10.1016/j.ijrobp.2019.04.006. Epub 2019 Apr 16.

PMID:
31002941
5.

SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.

Alayed Y, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Musunuru HB, Davidson M, Ravi A, Ho L, Deabreu A, D'Alimonte L, Bhounr Z, Zhang L, Commisso K, Loblaw A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):36-41. doi: 10.1016/j.ijrobp.2018.11.011. Epub 2018 Nov 14.

PMID:
30445172
6.

Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.

Musunuru HB, D'Alimonte L, Davidson M, Ho L, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Ravi A, Deabreu A, Zhang L, Commisso K, Loblaw A.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1438-1447. doi: 10.1016/j.ijrobp.2018.07.2005. Epub 2018 Jul 31.

PMID:
30071295
7.

Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.

Alayed Y, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Commisso K, Commisso A, Zhang L, Quon HC, Musunuru HB, Helou J, Loblaw DA.

Radiother Oncol. 2018 May;127(2):213-218. doi: 10.1016/j.radonc.2018.03.005. Epub 2018 Mar 24.

PMID:
29588072
8.

Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.

Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A.

Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15.

PMID:
29551231
9.

A photonic platform for donor spin qubits in silicon.

Morse KJ, Abraham RJS, DeAbreu A, Bowness C, Richards TS, Riemann H, Abrosimov NV, Becker P, Pohl HJ, Thewalt MLW, Simmons S.

Sci Adv. 2017 Jul 26;3(7):e1700930. doi: 10.1126/sciadv.1700930. eCollection 2017 Jul.

10.

Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?

Helou J, D'Alimonte L, Quon H, Deabreu A, Commisso K, Cheung P, Chu W, Mamedov A, Davidson M, Ravi A, Loblaw A.

Radiother Oncol. 2017 Jun;123(3):478-482. doi: 10.1016/j.radonc.2017.03.006. Epub 2017 Apr 19.

PMID:
28433413
11.

Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.

Shahid N, Loblaw A, Chung HT, Cheung P, Szumacher E, Danjoux C, Sankreacha R, Zhang L, Deabreu A, Mamedov A, Morton G.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):412-420. doi: 10.1016/j.clon.2017.01.042. Epub 2017 Feb 9.

PMID:
28190638
12.

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.

Quon HC, Musunuru HB, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Zhang L, Loblaw A.

Front Oncol. 2016 Aug 29;6:185. doi: 10.3389/fonc.2016.00185. eCollection 2016.

13.

Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.

Musunuru HB, Davidson M, Cheung P, Vesprini D, Liu S, Chung H, Chu W, Mamedov A, Ravi A, D'Alimonte L, Commisso K, Helou J, Deabreu A, Zhang L, Loblaw A.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1043-51. doi: 10.1016/j.ijrobp.2015.12.010. Epub 2015 Dec 23.

PMID:
27026311
14.

Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.

Musunuru HB, Quon H, Davidson M, Cheung P, Zhang L, D'Alimonte L, Deabreu A, Mamedov A, Loblaw A.

Radiother Oncol. 2016 Jan;118(1):112-7. doi: 10.1016/j.radonc.2015.12.020. Epub 2016 Jan 12.

PMID:
26796591
15.

High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success.

Helou J, D'Alimonte L, Loblaw A, Chung H, Cheung P, Szumacher E, Danjoux C, Ravi A, Deabreu A, Zhang L, Morton G.

Radiother Oncol. 2015 Apr;115(1):84-9. doi: 10.1016/j.radonc.2015.02.023. Epub 2015 Mar 11.

PMID:
25770875
16.

Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study.

Gladwish A, Loblaw A, Cheung P, Morton G, Chung H, Deabreu A, Pang G, Mamedov A.

Clin Oncol (R Coll Radiol). 2015 Mar;27(3):145-52. doi: 10.1016/j.clon.2014.12.003. Epub 2015 Jan 7.

PMID:
25577669
17.

A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost.

Helou J, Morton G, Zhang L, Deabreu A, D'Alimonte L, Elias E, Musunuru HB, Mamedov A, Ravi A, Chung H, Cheung P, Loblaw A.

Radiother Oncol. 2014 Dec;113(3):404-9. doi: 10.1016/j.radonc.2014.10.013. Epub 2014 Nov 14.

PMID:
25466371
18.

The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.

D'Alimonte L, Helou J, Sherman C, Loblaw A, Chung HT, Ravi A, Deabreu A, Zhang L, Morton G.

Brachytherapy. 2015 May-Jun;14(3):309-14. doi: 10.1016/j.brachy.2014.10.003. Epub 2014 Nov 25.

PMID:
25466361
19.

Prostatic displacement during extreme hypofractionated radiotherapy using volumetric modulated arc therapy (VMAT).

Gladwish A, Pang G, Cheung P, D'Alimonte L, Deabreu A, Loblaw A.

Radiat Oncol. 2014 Nov 28;9:262. doi: 10.1186/s13014-014-0262-y.

20.

Improving clinical trial accrual through a novel feedback approach: Lessons learned from a single disease site group.

D'Alimonte L, Deabreu A, Marquez A, Mamedov A, Loblaw A.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):70-3. doi: 10.1016/j.prro.2014.05.009. Epub 2014 Jul 3.

PMID:
25413410
21.

Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.

Elias E, Helou J, Zhang L, Cheung P, Deabreu A, D'Alimonte L, Sethukavalan P, Mamedov A, Cardoso M, Loblaw A.

Radiother Oncol. 2014 Jul;112(1):83-8. doi: 10.1016/j.radonc.2014.06.009. Epub 2014 Jul 5.

PMID:
25005578
22.

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.

Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L, Tang C, Quon H, Jain S, Pang G, Nam R.

Radiother Oncol. 2013 May;107(2):153-8. doi: 10.1016/j.radonc.2013.03.022. Epub 2013 May 3.

PMID:
23647750
23.

The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancer.

Jain S, Loblaw DA, Morton GC, Danjoux C, Szumacher E, Chu W, Chung HT, Vesprini D, Sahgal A, Zhang L, Deabreu A, Cheung PC.

Radiother Oncol. 2012 Nov;105(2):193-7. doi: 10.1016/j.radonc.2012.09.020. Epub 2012 Nov 22.

PMID:
23182057
24.

Intra-fraction motion during extreme hypofractionated radiotherapy of the prostate using pre- and post-treatment imaging.

Quon H, Loblaw DA, Cheung PC, Holden L, Tang C, Pang G, Morton G, Mamedov A, Deabreu A.

Clin Oncol (R Coll Radiol). 2012 Nov;24(9):640-5. doi: 10.1016/j.clon.2011.12.001. Epub 2012 Jan 9.

PMID:
22226683
25.

Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.

Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Kiss A, Mamedov A, Deabreu A.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):617-23. doi: 10.1016/j.ijrobp.2011.07.005. Epub 2011 Nov 11.

PMID:
22079736
26.

Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?

Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C, Chung HT, Deabreu A, Mamedov A, Zhang L, Sankreacha R, Vigneault E, Springer C.

Radiother Oncol. 2011 Sep;100(3):463-7. doi: 10.1016/j.radonc.2011.08.022. Epub 2011 Sep 14.

PMID:
21924511
27.

Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.

Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):898-905. doi: 10.1016/j.ijrobp.2010.11.003. Epub 2011 Jan 14.

PMID:
21237581
28.

Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer.

Morton GC, Loblaw DA, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1299-305. doi: 10.1016/j.ijrobp.2010.04.046. Epub 2010 Aug 12.

PMID:
20708853
29.

Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.

Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):811-7. doi: 10.1016/j.ijrobp.2009.05.054. Epub 2009 Oct 14.

PMID:
19836166
30.

A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.

Spaner DE, Hammond C, Mena J, Foden C, Deabreu A.

Cancer Immunol Immunother. 2005 Jul;54(7):635-46. Epub 2004 Dec 17.

PMID:
15918075

Supplemental Content

Loading ...
Support Center